Health
Combo monoclonal antibody drugs may lower coronavirus loads – CIDRAP
Bamlanivimab paired with etesevimab was more effective than bamlanivimab alone.
Mildly to moderately ill COVID-19 adult outpatients given a combination of the monoclonal antibodies bamlanivimab and etesevimab early in the disease had significantly lower viral loads at day 11 than those who received a placebo, but a similar effect was not seen in those given bamlanivimab alone, a study published today in JAMA finds.
Bamlanivimab manufacturer Eli Lilly sponsored the double-blind phase 2/3 BLAZE-1 clinical trial, which involved 533 COVID-19 patients at 49 US medical centers. The…
-
General16 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News16 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
General22 hours ago‘We are here for you’: PM to bring help to flood zones
-
Business18 hours ago10 ASX shares to buy after the market selloff